US neurology最新文献_第6页

Imaging, Technology, and Parkinson’s Disease 成像，技术和帕金森病

US neurology Pub Date : 2019-01-01 DOI: 10.17925/USN.2019.15.1.18

Nora Vanegas

{"title":"Imaging, Technology, and Parkinson’s Disease","authors":"Nora Vanegas","doi":"10.17925/USN.2019.15.1.18","DOIUrl":"https://doi.org/10.17925/USN.2019.15.1.18","url":null,"abstract":"Nora Vanegas Dr Vanegas is a neurologist who specializes in deep brain stimulation (DBS) and the treatment of movement disorders including Parkinson’s disease, dystonia, and essential tremor. Dr Vanegas completed her combined clinical-research fellowship at the National Institutes of Health (NIH) under the mentorship of Dr Mark Hallett. Her training had a special focus on neuroimaging and neuromodulation. She transitioned to being an Assistant Professor of Neurology in Columbia University in 2016, and is now an established local expert in neuromodulation for movement disorders. Dr Vanegas is also a clinical investigator whose research involves clinical and translational areas of movement disorders, specifically the use of brain imaging for the understanding of DBS and the physiology of the basal ganglia. As part of multi-disciplinary research activities, Dr Vanegas has developed strong collaborations for various projects with the departments of Biomedical Engineering, Speech Pathology, Neurosurgery and Psychiatry at Columbia University. Such collaborative research activities include the use of instrumented assessments to measure gait characteristics in patients with Parkinson’s disease, the benefits of various airway protection interventions in patients with Parkinson’s disease who aspirate with food and the activity of brain neurons during decision making tasks.","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hot Topics in Epilepsy—Highlights of the American Epilepsy Society Annual Meeting 2018 癫痫病热点话题- 2018年美国癫痫学会年会亮点

US neurology Pub Date : 2019-01-01 DOI: 10.17925/USN.2019.15.1.22

N. Ayub, D. Goldenholz, S. Uliel-Sibony, M. Sajatovic, H. Thomas, S. Arnold, P. Voinescu, Zhibin Chen, Neurological Psychiatry-Adult Psychiatry

引用次数: 0

American Parkinson Disease Association Explores the Current Research in Diverse Parkinson’s Disease Populations 美国帕金森氏病协会探讨目前不同帕金森氏病人群的研究

US neurology Pub Date : 2019-01-01 DOI: 10.17925/usn.2019.15.2.63

R. Gilbert

引用次数: 2

Challenges of Interpreting Dystrophin Content by Western Blot 用Western Blot解释肌营养不良蛋白含量的挑战

US neurology Pub Date : 2019-01-01 DOI: 10.17925/USN.2019.15.1.40

F. Schnell, D. Frank, S. Fletcher, R. Johnsen, S. Wilton

引用次数: 7

Pediatric Migraine—An Updated Review 儿科偏头痛:最新综述

US neurology Pub Date : 2019-01-01 DOI: 10.17925/usn.2019.15.2.68

V. Popova, T. Berk

引用次数: 2

Rational Prescribing for Migraine Prevention 预防偏头痛的合理处方

US neurology Pub Date : 2019-01-01 DOI: 10.17925/usn.2019.15.2.75

D. Friedman

引用次数: 2

Case Management Services to Meet the Complex Needs of Patients with Multiple Sclerosis in the Community—The Successes and Challenges of a Unique Program from the National Multiple Sclerosis Society 病例管理服务，以满足社区多发性硬化症患者的复杂需求——来自国家多发性硬化症协会的一个独特项目的成功与挑战

US neurology Pub Date : 2019-01-01 DOI: 10.17925/USN.2019.15.1.27

R. Kalb, K. Costello, L. Guiod

{"title":"Case Management Services to Meet the Complex Needs of Patients with Multiple Sclerosis in the Community—The Successes and Challenges of a Unique Program from the National Multiple Sclerosis Society","authors":"R. Kalb, K. Costello, L. Guiod","doi":"10.17925/USN.2019.15.1.27","DOIUrl":"https://doi.org/10.17925/USN.2019.15.1.27","url":null,"abstract":"In spite of the therapies currently available to treat people with multiple sclerosis (MS), some individuals continue to experience physical, cognitive, and/or emotional changes over the course of the disease that severely compromise function, independence, safety, and quality of life. In addition, co-morbidities are common in people with MS, further impacting health and well-being, as well as the ability to manage their healthcare needs and cope with everyday life. The National MS Society’s Edward M Dowd Personal Advocate Program (which is one component of the National MS Society’s MS Navigator® Service) is designed to pick up where traditional neurologic care and Society MS Navigators cannot go—into patients’ home environments. This centrally administered program contracts with local professional case managers (most often nurses and social workers) to help stabilize individuals with multiple urgent care needs (for example, in cases of abuse or neglect, or inadequate food, housing or medical care, among others) while identifying and implementing longer-term, sustainable solutions leading to greater independence and quality of life. This article outlines the rationale and goals of the Society’s case management services, considers successful and unsuccessful outcomes that have occurred since the program’s inception, examines the factors that contribute to success or failure for any given patient, and describes future goals.","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Existing and Emerging Approaches to Treating Chronic Inflammatory Demyelinating Polyneuropathy 治疗慢性炎症性脱髓鞘性多神经病变的现有和新兴方法

US neurology Pub Date : 2019-01-01 DOI: 10.17925/USN.2019.15.1.33

H BrannaganIiiThomas, K. Farhad, I. Kleyman, M. Leitch, Rebecca E. Traub, C. Ulane

{"title":"Existing and Emerging Approaches to Treating Chronic Inflammatory Demyelinating Polyneuropathy","authors":"H BrannaganIiiThomas, K. Farhad, I. Kleyman, M. Leitch, Rebecca E. Traub, C. Ulane","doi":"10.17925/USN.2019.15.1.33","DOIUrl":"https://doi.org/10.17925/USN.2019.15.1.33","url":null,"abstract":"Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disabling disease with an incompletely understood autoimmune etiology. Differentiating the condition from other neurological diseases can be challenging and appropriate treatment is often delayed. Intravenous immunoglobulin (IVIg), plasmapheresis, corticosteroids and subcutaneous immunoglobulin (SCIg) have all been demonstrated to be beneficial in placebo-controlled, randomized clinical trials. Corticosteroids, including methylprednisolone and dexamethasone are effective and frequently used in CIDP but their long-term use is limited by side effects. One of the most commonly prescribed treatments for CIDP is IVIg which diminishes inflammatory processes and prevents disease progression. Treatment with IVIg has proven effective in randomized, double blind, placebo controlled, clinical trials and the results support its use in CIDP. For some patients, the benefit of IVIg, is limited by the frequency of infusions and systemic side effects such as flu-like symptoms, headache, and nausea. Other effective treatments for CIDP include corticosteroids that are associated with serious side effects in long-term use and plasmapheresis which requires specialized facilities. More recently, SCIg has been demonstrated in double blind, placebo-controlled studies to be effective for maintenance use in CIDP in patients whose disease has been controlled by IVIg. In a large clinical trial, 0.2 g/kg and 0.4 g/kg body weight doses of 20% SCIg equivalent to 1 mL/kg or 2 mL/kg, respectively, administered weekly, demonstrated efficacy in CIDP and were well tolerated. Immunomodulating treatments such as cyclophosphamide, mycophenolate mofetil and rituximab have also shown efficacy in select populations with CIDP.","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular Pathogenesis of Alzheimer’s Disease 阿尔茨海默病的分子发病机制

US neurology Pub Date : 2019-01-01 DOI: 10.17925/USN.2019.15.1.14

L. Tjernberg, Sophia Schedin Weiss

引用次数: 0

Non-motor Symptoms of Parkinson’s Disease—Considerations for Subclinical and Atypical Seizures 帕金森病的非运动症状——对亚临床和非典型癫痫发作的考虑

US neurology Pub Date : 2019-01-01 DOI: 10.17925/usn.2019.15.2.91

A. Son, S. Agarwal, A. Cucca, Kush Sharma, M. Biagioni

引用次数: 0